Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a daily glass of kefir during pregnancy ward off gestational diabetes?

NCT ID NCT07682077

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study investigates whether drinking kefir, a fermented dairy drink rich in live bacteria and yeasts, from around 14 weeks of pregnancy until routine diabetes screening can improve blood sugar control and reduce the risk of gestational diabetes. Pregnant individuals are randomly assigned to consume 250 mL of kefir daily or continue their usual prenatal care. Researchers measure blood glucose, insulin, gut microbiome changes, and other metabolic markers to see if this simple dietary addition makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Kefir (fermented dairy beverage)
What this could lead to
If effective, drinking kefir during pregnancy could become a simple, food-based way to help prevent gestational diabetes and improve metabolic health for mothers and babies.
What could go wrong
This is a small, early-stage study with 60 participants, so results may not apply to all pregnant people. Kefir may cause digestive discomfort, and its benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant individual with a singleton pregnancy * 19 years and older of age * Gestational age 14,3 weeks or less at enrolment * Able and willing to attend four in-person study visits at the PEADS Laboratory: baseline, 18-20 weeks' gestation, 26-28 weeks' gestation, and 1 month postpartum * Willing and able to comply with study group assignment, including daily consumption of 250 mL of kefir if assigned to the intervention group * Willing to avoid kefir consumption until completion of the 26-28-week study visit if assigned to the control group * Willing to provide required biological and clinical samples, including stool samples and glucose/insulin data, according to the study protocol * No probiotic, prebiotic, synbiotic, or antibiotic use during the first trimester or at enrollment * Not currently consuming probiotic, prebiotic, synbiotic, or antiobiotic supplements * Willing to avoid probiotic, prebiotic, and synbiotic supplements until completion of the 26-28-week study visit. * Does not engage in regular moderate-to-vigorous physical activity * No recent or active infectious illness or significant gastrointestinal symptoms, including diarrhea or constipation in the first trimester of pregnancy. * No history of bariatric surgery * Able to communicate in English or French * Currently living in Fredericton, New Brunswick, and not planning to relocate before the 1-month postpartum visit Exclusion Criteria: * Pre-existing metabolic disease affecting glucose regulation, including type 1 diabetes or type 2 diabetes * Current use or first trimester use of medications known to alter glucose metabolism, such as metformin or semaglutide * Gastrointestinal or inflammatory disease, including Crohn's disease, ulcerative colitis, celiac disease, or diagnosed irritable bowel syndrome * Allergy, intolerance, or other contraindication to dairy or components of kefir

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood glucose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.